肌节性与非肌节性肥厚型心肌病的疾病轨迹、合并症与死亡率差异
本研究基于SHaRe多中心纵向队列,对6120例基因分型的肥厚型心肌病患者进行分析,中位随访5.3年。肌节性HCM患者诊断年龄更轻,房颤、左室收缩功能障碍和室性心律失常负担更高,全因死亡率相似但死亡年龄更早,HCM相关死亡率更高。房颤是最强的疾病修饰因素,在肌节性HCM中影响更大。基因型可优化风险分层和临床管理。
要点
- 肌节性HCM诊断更年轻,房颤、左室收缩功能障碍及室性心律失常年龄标化发生率更高。
- 两组全因死亡率相似,但肌节性HCM死亡年龄更早,HCM相关死亡率更高。
- 房颤是 strongest 疾病修饰因素,在肌节性HCM中不良结局影响更大。
核心结论
- 基因型可优化HCM风险分层并指导临床管理。
- 肌节性HCM预后更差,应加强心律失常和收缩功能监测,降低晚期治疗门槛。
- 高血压和肥胖等合并症可能是非肌节性HCM的可干预危险因素。
研究设计与样本
- 多中心纵向队列研究,纳入SHaRe注册中基因分型的HCM患者。
- 共6120例患者,40%女性,87%为先证者,50%为肌节性HCM,中位随访5.3年。
- 采用时变Cox比例风险模型评估遗传分类和合并症对心血管事件序列的影响。
主要发现
- 肌节性HCM(n=3082)诊断年龄中位数38.1岁,非肌节性为54.3岁(P<0.001)。
- 肌节性HCM女性比例更高,肥胖、高血压和左室流出道梗阻比例更低。
- 年龄标化后,肌节性HCM房颤ASI比1.28(CI 1.16-1.40),左室收缩功能障碍ASI比1.31(CI 1.15-1.48),室性心律失常ASI比1.37(CI 1.17-1.52)。
- 全因死亡率相似(10.4% vs 9.4%,P=0.20),但肌节性HCM死亡年龄更早(平均7.8年,P<0.001),模型估计44至85岁间损失3.5生命年。
- 肌节性HCM的HCM相关死亡率更高(HR 1.61,CI 1.18-2.20)。
临床怎么用
- 对肌节性HCM患者加强房颤、左室收缩功能障碍和室性心律失常的监测。
- 肌节性HCM患者考虑降低晚期治疗(如ICD、移植评估)的门槛。
- 对非肌节性HCM患者积极管理高血压和肥胖等可干预合并症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcomere gene variants are a key cause of hypertrophic cardiomyopathy (HCM), and have been associated with worse prognosis. However, it is unclear how comorbidities influence clinical trajectories, the timing of events, and causes of death in sarcomeric and nonsarcomeric HCM. METHODS: We conducted a multicenter longitudinal cohort study of genotyped patients with HCM in the Sarcomeric Human Cardiomyopathy registry (SHaRe). Patients were classified as sarcomeric HCM (pathogenic/likely pathogenic sarcomere variant) or nonsarcomeric HCM (genetically elusive). The influence of genetic classification and comorbidities on the sequence of cardiovascular events were assessed in time-varying Cox proportional hazards models. RESULTS: Among 6120 patients (40% women; 87% probands; 50% sarcomeric HCM), followed for a median of 5.3 years, sarcomeric HCM (n=3082) was associated with a younger age at diagnosis (median 38.1 versus 54.3 years; P<0.001), a higher proportion of women and less obesity, hypertension, and left ventricular (LV) obstruction. After age standardization, sarcomeric HCM was associated with a higher burden of atrial fibrillation (age-standardized incidence [ASI] ratio, 1.28 [CI, 1.16-1.40]), LV systolic dysfunction (ASI ratio, 1.31 [CI, 1.15-1.48]), and ventricular arrhythmias (ASI ratio, 1.37 [CI, 1.17-1.52]) than nonsarcomeric HCM. All-cause mortality was similar (10.4% versus 9.4%; P=0.20); however, patients with sarcomeric HCM died younger (mean 7.8 years; P<0.001), with model-based survival-analysis estimating 3.5 life-years lost between ages 44 and 85. Sarcomeric HCM was also associated with higher HCM-related mortality (hazard ratio [HR], 1.61 [CI, 1.18-2.20]). Temporal analysis identified atrial fibrillation as the strongest disease-modifier, increasing the risk of LV systolic dysfunction (HR, 2.54 [CI 2.07-3.11]), ventricular arrhythmias (HR, 3.13 [CI, 2.36-4.20]), and mortality (HR, 1.94 [CI, 1.64-2.31]) in both groups. Genotype-interaction analyses demonstrated a larger impact of atrial fibrillation and LV systolic dysfunction on adverse outcomes in sarcomeric versus nonsarcomeric HCM, with effect ratios up to 1.98 for severe heart failure and 2.01 for mortality (both P<0.01). CONCLUSIONS: Genotype can refine risk stratification and inform clinical management in HCM. Sarcomeric HCM is associated with worse prognosis and may benefit from more vigilant surveillance for arrhythmias and systolic dysfunction, with a lower threshold for advanced therapies. Comorbidities, including hypertension and obesity, may be modifiable risk factors for patients with nonsarcomeric HCM.
引用
- Vissing CR, Axelsson Raja A, Helms AS, et al. Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. Circulation. 2026. PMID: 41800474. doi:10.1161/CIRCULATIONAHA.125.076036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。